,i #aagth ,,congress #b;d ,session ,h4 ,r4 #fgeg ,,in ,,the ,,house ,,of ,,representatives ,february #ah1 #bjbb,mr4 ,burgess 7for himself and ,mrs4 ,miller-,meeks7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend title ,,xviii of the ,social ,security ,act to establish under the ,medicare prescription drug program a minimum amount of price concessions for insulin to be passed through to beneficiaries at the point-of-sale1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,insulin ,savings for ,patients ,act 4 #b4 ,negotiated price concessions for insulin at point-of-sale under part ,d of ,medicare program 7a7 ,in general ,section #ahfj;,d-#b7;d77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7;d77#a77 is amended-- 7#a7 in subparagraph 7,a71 by striking ,under and inserting ,subject to subparagraph 7,d71 under2 and 7#b7 by adding at the end the following new subparagraph3 7,d7 ,negotiated price concessions for insulin at point-of-sale 7i7 ,in general ,for drugs dispensed in plan year #bjbb or a subsequent plan year1 the minimum percentage described in clause 7ii7 for such plan year of price concessions negotiated between manufacturers and a prescription drug plan or ,,ma-,,pd plan 7or any entity that provides pharmacy benefits management services under a contract with any such prescription drug plan or ,,ma-,,pd plan7 and taken into account under subparagraph 7,b7 in determining negotiated prices for the plan year for covered part ,d drugs that are insulin provided under such a plan shall be provided to enrollees of such a plan at pharmacies or by mail order service at the point-of-sale of such drugs4 7ii7 ,amount of price concession ,for purposes of clause 7i71 and subject to clause 7iii71 the minimum percentage described in this clause is-- 7,i7 for drugs dispensed in plan year #bjbb1 #ej percent2 7,,ii7 for drugs dispensed in plan year #bjbc1 #ge percent2 and 7,,iii7 for drugs dispensed in plan year #bjbd or a subsequent plan year1 #ajj percent4 7iii7 ,modification of minimum percentage ,for plan years beginning on or after ,january #a1 #bjbd1 the ,secretary may1 through notice and comment rulemaking1 specify a percentage other than the percentage described in clause 7ii7 for a plan year1 except that in specifying such percentage the ,secretary shall not specify a percentage that is less than #ej percent of the negotiated price concession for such plan year4 ,any percentage specified pursuant to the authority of the previous sentence for a plan year that would be less than the percentage otherwise described in clause 7ii7 for the plan year may only be applied if such reduction in percentage is justified as a benefit to individuals enrolled under this title4 4 7b7 ,inclusion of information in bid submission ,section #ahfj;,d-#aa7;b77#b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aa7;b77#b77 is amended-- 7#a7 by redesignating subparagraph 7,f7 as subparagraph 7,g72 and 7#b7 by inserting after subparagraph 7,e7 the following new subparagraph3 7,f7 ,point-of-sale price concessions for insulin ,for plan years beginning on or after ,january #a1 #bjbb1 an estimate of the aggregate price concessions for all insulin negotiated by the plan for such plan year4 4 7c7 ,,gao study and report on insulin pricing ,not later than #b years after the date of the enactment of this ,act1 and annually thereafter1 the ,comptroller ,general of the ,united ,states shall-- 7#a7 conduct a study on the effects of the implementation of the requirement described in subparagraph 7,d7 of section #ahfj;,d-#b7;d77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7;d77#a771 as added by subsection 7a71 including an analysis of-- 7,a7 trends in the list and net prices of insulin for qualified prescription drug coverage offered by a prescription drug plan under part ,d of the ,social ,security ,act or an ,,ma-,,pd plan under part ,c of such title2 7,b7 savings on insulin for individuals enrolled in a prescription drug plan under part ,d of the ,social ,security ,act or an ,,ma-,,pd plan under part ,c of such title2 7,c7 trends in out-of-pocket costs for individuals enrolled in such plans1 as compared to individuals enrolled in a group health plan 7as defined in section #bgia7;a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ia7;a771 a ,state plan under title ,,xix of the ,social ,security ,act1 or a qualified health plan offered through an ,exchange established under title ,i of the ,patient ,protection and ,affordable ,care ,act 7#db ,u4,s4,c4 #ahjja et seq472 and 7,d7 approval and market entry of biosimilar insulin under section #cea7k7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb72 and 7#b7 submit to the ,committee on ,energy and ,commerce and the ,committee on ,ways and ,means in the ,house of ,representatives1 and the ,committee on ,finance in the ,senate1 a report on the study conducted under paragraph 7#a71 with recommendations on how to enhance the access of individuals enrolled in a prescription drug plan under part ,d of the ,social ,security ,act or an ,,ma-,,pd plan under part ,c of such title to lower out-of-pocket costs for insulin4 7d7 ,transparency ,section #ahfj;,d-#a7;c77#c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aja7;c77#c77 is amended by adding at the end the following new subparagraph3 7,c7 ,additional information ,for plan year #bjbb and each subsequent plan year1 such information referred to in paragraph 7#b77;,a7 shall also include1 for a plan year1 information regarding the requirement described in subparagraph 7,d7 of section #ahfj;,d-#b7;d77#a7 with respect to insulin negotiated by the plan for such plan year4 4